Hot Promising Companies To Own For 2015

Hot Promising Companies To Own For 2015: AstraZeneca PLC (AZN)

AstraZeneca PLC (AstraZeneca), incorporated on June 17, 1992, is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments for illnesses, such as its antibiotic, Merrem/Meronem and Losec/Prilosec for acid related diseases. AstraZeneca's products include Crestor, Atacand,Seloken/Toprol-XL, Plendil, Onglyza, Zestril, Symbicort and Zoladex. The Company owns and operates a range of research and development (R&D), production and marketing facilities worldwide. AstraZeneca operates in over 100 countries, including China, Mexico, Brazil and Russia. On August 31, 2011, the Company completed the sale of the Astra Tech business to DENTSPLY International Inc. On June 19, 2012, the Company acquired Ardea Biosciences Inc (Ardea), a biotechnology compa ny in San Diego, California. In July 2012, the Company acquired a portfolio of neuroscience assets from Link Medicine Corporation. In August 2012, Alliance Pharma plc's wholly owned subsidiary, Alliance Pharmaceuticals Limited, acquired the antimalarial brands Paludrine, Avloclor and Savarine from AstraZeneca UK Limited. In August 2012, the Company and Bristol-Myers Squibb Company announced the acquisition of Amylin Pharmaceuticals, Inc. by Bristol-Myers Squibb Company. In June 2013, the Company acquired Pearl Therapeutics.

Cardiovascular

The Company's marketed products include Crestor (rosuvastatin calcium), Atacand2 (candesartan cilexetil), Seloken/Toprol-XL (metoprolol succinate), Tenormin (atenolol), Plendil (felodipine), Zestril3 (lisinopril dihydrate), Brilinta/Brilique (ticagrelor), and Axanum, (acetylsalicylic acid (ASA). Crestor1 is a ! statin used for the treatment of dyslipidaemia and hypercholesterolemia. In some markets, it is also in dicated to slow the progression of atherosclerosis and to re! duce the risk of first cardiovascular (CV) events. Atacand2 is an angiotensin II antagonist used for the 1st line treatment of hypertension and symptomatic heart failure. Seloken/Toprol-XL is a beta-blocker once-daily tablet used for 24-hour control of hypertension and for use in heart failure and angina.

Tenormin is a cardioselective beta-blocker used for hypertension, angina pectoris and other CV disorders. Plendil is a calcium antagonist used for the treatment of hypertension and angina. Zestril3 is an angiotensin-converting enzyme inhibitor used for the treatment of a wide range of CV diseases, including hypertension. Brilinta/Brilique is an oral antiplatelet for the treatment of acute coronary syndromes (ACS). Axanum is a fixed dose combination indicated for prevention of CV events in high-risk CV patients in need of daily low-dose ASA treatment and who are at risk of gastric ulcers.

The Company's marketed products for diabetes include Kombog lyze ((saxagliptin and metformin HCl), Kombiglyze XR (saxagliptin and metformin XR) and Onglyza (saxagliptin). Komboglyze is an immediate release fixed dose combination indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with Type 2 diabetes mellitus inadequately controlled on their maximally tolerated dose of metformin alone or those already being treated with the combination of saxagliptin and metformin as separate tablets. Kombiglyze XR is an extended release fixed dose combination indicated as an adjunct to diet and exercise to improve glycaemic control in adults with Type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate. Onglyza is a DPP-IV inhibitor used for the treatment of Type 2 diabetes.

Gastrointestinal

AstraZeneca's marketed products include Nexium (es! omeprazol! e), Losec/Prilosec (omeprazole) and Entocort (budesonide). Nexium is a proton pump inhibitor (PPI) us ed for the treatment of acid-related diseases to offer clini! cal impro! vements over other PPIs and other treatments. Losec/Prilosec is used for the short-term and long-term treatment of acid-related diseases. Entocort is a corticosteroid used for the treatment of inflammatory bowel disease. Nexium is marketed in approximately 120 countries and is available in oral (tablet/capsules and oral suspension) and intravenous (i.v.) dosage forms for the treatment of acid-related diseases.

Infection

The Company's marketed products include Merrem/Meronem (meropenem), Cubicin (daptomycin) and FluMist/Fluenz (influenza vaccine live, intranasal). Merrem/Meronem is a carbapenem anti-bacterial used for the treatment of serious infections in hospitalised patients. Cubicin is a cyclic lipopeptide anti-bacterial used for the treatment of serious infections in hospitalised patients. FluMist/Fluenz is an intranasal live, attenuated, trivalent influenza vaccine.

Neuroscience

AstraZeneca's marketed products inc lude Seroquel IR (quetiapine fumarate), Seroquel XR (an extended release formulation of quetiapine fumarate), Zomig (zolmitriptan), Diprivan (propofol), Vimovo (naproxen/esomeprazole magnesium), Naropin (ropivacaine), Xylocaine (lidocaine) and EMLA (lidocaine and prilocaine). Seroquel IR is an atypical anti-psychotic drug used for the treatment of schizophrenia and bipolar disorder (mania, depression and maintenance). Seroquel XR is used for the treatment of schizophrenia, bipolar disorder, MDD and in some territories for generalised anxiety disorder (GAD).

Zomig is used for the treatment of migraines with or without aura and Zomig Nasal Spray is indicated for the acute treatment of cluster. Diprivan is an intravenous general anaesthetic used in the induction and maintenance of general anaesthesia, for use in intensive care sedation and consci! ous sedat! ion for surgical as well as diagnostic procedures. Vimovo is a fixed-dose combination of enteric-coated naproxe n (an NSAID) with the gastroprotection of immediate release ! esomepraz! ole (a proton pump inhibitor) for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, and to decrease the developing of gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. Naropin is used as a long-acting local anaesthetic, for surgical anaesthesia and acute pain management. Xylocaine is a used short-acting local anaesthetic. EMLA is used as a local anaesthetic for topical application.

Oncology

AstraZeneca's marketed products include Arimidex (anastrozole), Zoladex (goserelin acetate implant), Casodex (bicalutamide), Iressa (gefitinib), Faslodex (fulvestrant), Nolvadex (tamoxifen citrate) and Caprelsa (vandetanib). Arimidex is an aromatase inhibitor used for the treatment of early breast cancer. Zoladex, in one- and three-month depots, is a luteinising hormone-releasing hormone agonist used for the treatment of prostate cancer, breast cancer and certain benign gynaecol ogical disorders. Casodex is an anti-androgen therapy used for the treatment of prostate cancer.

Advisors' Opinion:

• [By MONEYMORNING.COM]

  For instance, as I wrote this, Pfizer Inc. (NYSE: PFE) was still pursuing a $100 billion-plus merger with AstraZeneca PLC (NYSE ADR: AZN).

  The recent retreat of biotech stocks from a blistering two-year rally really wasn't about fundamentals.

• [By TaniaC] biopharmaceutical company. AstraZeneca's products include Crestor, Atacand, Seloken/Toprol-XL, Plendil, Onglyza, Zestril, Symbicort and Zoladex. The company owns and operates a range of research and development (R&D), production and marketing facilities worldwide. AstraZeneca operates in over 100 countries, including China, Mexico, Brazil and Russia.

  Focus on the Diabetes Segment

  ! For Astra! Zeneca, its diabetes business grew 60% in the third quarter of fiscal 2013 and contributed to overall growth of 8%. The diabetes franchise made $206 million. U.S. health regulators approved an AstraZeneca drug from a new class of medicines to treat type 2 diabetes after previously rejecting it over safety concerns. The medicine was co-developed by Bristol-Myers Squibb Co. (BMY) and AstraZeneca. AstraZeneca late last year bought out Bristol's stake in its diabetes joint venture for more than $4 billion, including up-front and sales-related milestone payments.

  Farxiga, which has already been available in Europe, belongs to a class of diabetes drugs called SGLT-2 inhibitors that work by blocking reabsorption of glucose by the kidney and increasing its excretion through urine to lower levels of blood sugar.

  It will compete with a similar drug from Johnson & Johnson (JNJ) called Invokana, as well as diabetes medicines from other classes.

  Details of the Drug

  "Farxiga provides an additional treatment option for millions of Americans with type 2 diabetes," Curtis Rosebraugh, of the FDA's Center for Drug Evaluation and Research, said in a statement. The FDA had initially rejected the Astra and Bristol-Myers drug in early 2012 over concerns about possible cancer and heart risks. The companies provided additional data that addressed those concerns to the satisfaction of the advisory panel and the agency.

  Still, as a condition of approval, the FDA is requiring six post-marketing studies, including a cardiovascular outcomes trial to mak

• [By Luke Jacobi]

  Shares of AstraZeneca PLC (NYSE: AZN) were down 12.01 percent to $70.64 after the company's board rejected the new $119 billion takeover offer from Pfizer (NYSE: PFE).

• [By Jake L'Ecuyer]

  Equities Trading DOWN
  Shares of AstraZeneca PLC (NYSE: AZN) were 11.70 percent to $70.89 after the company's board rejected the new $119 billion takeover offer from Pfizer (NYSE: PFE). 3-ear! nings-low! ers-fy14-guidance"> reported a rise in its fiscal third-quarter earnings and cut its FY14 forecast.

source from Top Stocks For 2015:http://www.topstocksblog.com/hot-promising-companies-to-own-for-2015.html